The S-3 is a standard resale registration with no immediate trading impact. Monitor for warrant exercises, which would provide additional cash runway. The stock may face overhang from potential selling by BVF, but the private placement already signaled insider commitment.
Price Chart
Executive Summary
Entera Bio filed an S-3 to register 19.6M ordinary shares for resale by BVF entities, issued in a $10M private placement on April 2, 2026. The company will not receive proceeds from resales but could gain up to $14.5M from warrant exercises. The filing is a contractual obligation, not a new capital raise, and follows a Q1 earnings beat.
Key Facts
- Registered up to 19,569,472 ordinary shares for resale by BVF selling shareholders, including shares and warrants from the April 2026 private placement.
- Private placement raised ~$10M at $1.2775 per unit (1 share + 1.5 warrants).
- Warrants have exercise price of $1.24 per share, exercisable after 6 months (Oct 2026), expiring in 5 years.
- If all ordinary share warrants are cash-exercised, Entera could receive ~$14.5M additional proceeds.
- Q1 2026 net loss of $3.5M ($-0.07/share) beat consensus by 12.5%.
- Cash and cash equivalents were $13.6M as of March 31, 2026, excluding the $10M private placement closed April 2.
- Company plans to use proceeds for Phase 3 EB613 osteoporosis study and working capital.
Financial Impact
Potential dilution of up to 39.8% if all registered shares are issued (19.6M vs 49.2M outstanding), but these shares are already outstanding or issuable from the private placement; the registration does not change economic dilution.
Risk Factors
- Potential overhang from resale of 19.6M shares by BVF entities.
- Geopolitical risks from operations in Israel amid regional conflicts.
- Clinical trial risks for EB613 Phase 3 and other pipeline candidates.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001178913-26-002460 |
| Exhibit: ex107.htm | 0001178913-26-002460 |
| Exhibit: exhibit_5-1.htm | 0001178913-26-002460 |
| Exhibit: exhibit_23-1.htm | 0001178913-26-002460 |
| Document: 0001178913-26-002460-index-headers.html | 0001178913-26-002460 |
| Document: 0001178913-26-002460-index.html | 0001178913-26-002460 |
| Document: 0001178913-26-002460.txt | 0001178913-26-002460 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | DEF 14A | $2.77 | awaiting T+60 | — | $2.86 (+3.25%) |
Oct 6, 2026 20d ago | 8-K | $2.53 | awaiting T+60 | — | $2.86 (+13.04%) |
Aug 27, 2026 8w ago | Press Release | $3.08 | awaiting T+60 | — | $2.86 (−7.14%) |
Aug 18, 2026 9w ago | 8-K | $2.89 | awaiting T+60 | — | $2.86 (−1.04%) |
Aug 7, 2026 11w ago | Press Release | $3.04 | awaiting T+60 | — | $2.86 (−5.92%) |
Jul 29, 2026 12w ago | Press Release | $3.00 $3.02 | ▲ +0.67% | ▼ −4.06% | $2.86 (−4.67%) |
Jun 16, 2026 18w ago | Press Release | $1.18 $2.79 | ▲ +136.44% | ▲ +135.44% | $2.86 (+142.37%) |
May 28, 2026 21w ago | Press Release | $1.22 $3.23 | ▲ +164.75% | ▲ +163.02% | $2.86 (+134.43%) |
May 18, 2026 23w ago | EFFECT | $1.23 $2.80 | ▲ +127.64% | ▲ +122.79% | $2.86 (+132.52%) |
May 8, 2026 24w ago | S-3 | $1.17 $2.81 | ▲ +140.17% | ▲ +135.78% | $2.86 (+144.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers